(Q37932036)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21916985%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

review article

1 reference

title

Host genomics and HCV treatment response (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21916985%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21916985%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Alexander J Thompson

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21916985%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

publication date

1 February 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21916985%20AND%20SRC:MED&resulttype=core&format=json

Journal of Gastroenterology and Hepatology

12 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21916985%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

volume

27

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21916985%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21916985%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

page(s)

212-222

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21916985%20AND%20SRC:MED&resulttype=core&format=json

How to interpret a genome-wide association study

12 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Common genetic variation and human traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Impact of viral amino acid substitutions and host interleukin-28b polymorphism on replication and susceptibility to interferon of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Limited use of interleukin 28B in the setting of response-guided treatment with detailed on-treatment virological monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Pre-treatment prediction of response to pegylated-interferon plus ribavarin for chronic hepatitis C using RVR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

The Effects of IL-28B and ITPA polymorphisms on treatment of hepatitis C virus genotype 6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Pharmacodynamics of PEG-IFN-[alpha]-2a and HCV response as a function of IL28B polymorphism in HIV/HCV-coinfected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

A whole-genome association study of major determinants for host control of HIV-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Treating hepatitis C infection in liver transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Impact of donor and recipient IL28B rs12979860 genotypes on hepatitis C virus liver graft reinfection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Estimating the net contribution of interleukin-28B variation to spontaneous hepatitis C virus clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Genetic variation in IL28B and treatment-induced clearance of hepatitis C virus in HIV-positive patients with acute and chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Viral genotype-specific role of PNPLA3, PPARG, MTTP, and IL28B in hepatitis C virus-associated steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Beneficial IL28B genotype associated with lower frequency of hepatic steatosis in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL-28, IL-29 and their class II cytokine receptor IL-28R

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Lambda interferon inhibits hepatitis B and C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Interleukin-29 functions cooperatively with interferon to induce antiviral gene expression and inhibit hepatitis C virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Antitumor activity of IFN-lambda in murine tumor models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Natural killer inhibitory receptor expression associated with treatment failure and interleukin-28B genotype in patients with chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Boceprevir for untreated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Boceprevir for previously treated chronic HCV genotype 1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Telaprevir for previously untreated chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Telaprevir for retreatment of HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X

Genetic variation in the interleukin -28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1746.2011.06918.X